A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2017
At a glance
- Drugs RG 7600 (Primary)
- Indications Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Genentech
- 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History